# 4O: Amivantamab plus lazertinib vs osimertinib in first-line (1L) EGFR-mutant (EGFRm) advanced NSCLC: Final overall survival (OS) from the phase III MARIPOSA study

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/4o-amivantamab-plus-lazertinib-vs-osimertinib-in-first-line-1l-egfr-mutant-egfrm/

## Facts

| Field | Value |
| --- | --- |
| Author Names | J.C-H. Yang,Yoon Jun Kim,SH Lee,B. Liu,Y.V. Ostapenko,Shun Lu,Adlinda Alip,Ernesto Korbenfeld,Josiane Mourão Dias,Pongwut Danchaivijitr,N. Girard,Enriqueta Felip,H. Hayashi,Alexander I. Spira,Benjamin Besse,Tingting Sun,Marguerite Ennis,Seema Sethi,Joshua Bauml,Byoung Chul Cho |
| Citations | 45 |
| DOI | 10.1016/s1556-0864(25)00199-6 |
| Fields | Medicine |
| Open Access | true |
| OA Status | bronze |
| OA URL | https://www.jto.org/article/S1556-0864(25)00199-6/pdf |
| OpenAlex ID | https://openalex.org/W4408978854 |
| Type | article |
| Year | 2025 |

## Paper authors

- [Adlinda Alip](https://scholariq.org/researchers/adlinda-alip/)

## Paper journal

- [Journal of Thoracic Oncology](https://scholariq.org/journals/journal-of-thoracic-oncology/)

## Paper primary topic

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)

## Paper topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Gastric Cancer Management and Outcomes](https://scholariq.org/topics/gastric-cancer-management-and-outcomes/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.